Kocayigit Ibrahim, Kocayigit Havva, Yaylaci Selcuk, Can Yusuf, Erdem Ali Fuat, Karabay Oguz
. Assistant Professor, University of Sakarya, Department of Cardiology, Sakarya, Turkey.
. Sakarya University Education and Research Hospital, Department of Anesthesiology, Sakarya, Turkey.
Rev Assoc Med Bras (1992). 2020 Sep 21;66Suppl 2(Suppl 2):71-76. doi: 10.1590/1806-9282.66.S2.71. eCollection 2020.
Coronavirus disease 2019 (COVID-19) is an emerging health threat caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Previous studies have noted hypertension is associated with increased mortality due to COVID-19; however, it is not clear whether the increased risk is due to hypertension itself or antihypertensive agents. We aimed to evaluate the impact of antihypertensive agents on the clinical outcomes of hypertensive patients with COVID-19.
Our study included 169 consecutive hypertensive patients hospitalized due to COVID-19 between March 20 and April 10, 2020. The demographic characteristics, clinical data, and type of antihypertensive agents being used were reviewed.
The mean age of patients was 65.8±11.7 years.30 patients(17.7%) died during hospitalization. A total of 142 patients(84%) were using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), 91 (53.8%) were using diuretics, 69 (40.8%) were using calcium channel blockers (CCBs), 66 (39.1%) were using beta-blockers, 12 (7.1%) were using alpha-blockers, and 5 (2.9%) were using mineralocorticoid receptor antagonists (MRAs). There was no significant difference between survivors and non-survivors based on the type of antihypertensive agents being used. Binary logistic regression analysis showed that the type of the antihypertensive agent being used had no effect on mortality [OR=0.527 (0.130-2.138), p=0.370 for ACEIs/ARBs; OR=0.731 (0.296-1.808), p=0.498 for CCBs; OR=0.673 (0.254-1.782), p=0.425 for diuretics; OR=1.846 (0.688-4.950), p=0.223 for beta-blockers; OR=0.389 (0.089-1.695), p=0.208 for alpha-blockers; and OR=1.372 (0.107-17.639), p=0.808 for MRAs].
The type of antihypertensive agent being used had no effect on the clinical course and mortality in hypertensive patients with COVID-19. The use of these agents should be maintained for the treatment of hypertension during hospitalization.
2019冠状病毒病（COVID-19）是由一种名为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的新型冠状病毒引发的新出现的健康威胁。既往研究指出，高血压与COVID-19导致的死亡率增加相关；然而，风险增加是由于高血压本身还是抗高血压药物尚不清楚。我们旨在评估抗高血压药物对COVID-19高血压患者临床结局的影响。
我们的研究纳入了2020年3月20日至4月10日期间因COVID-19住院的169例连续性高血压患者。回顾了人口统计学特征、临床数据以及所使用的抗高血压药物类型。
患者的平均年龄为65.8±11.7岁。30例患者（17.7%）在住院期间死亡。共有142例患者（84%）使用血管紧张素转换酶抑制剂（ACEI）或血管紧张素II受体阻滞剂（ARB），91例（53.8%）使用利尿剂，69例（40.8%）使用钙通道阻滞剂（CCB），66例（39.1%）使用β受体阻滞剂，12例（7.1%）使用α受体阻滞剂，5例（2.9%）使用盐皮质激素受体拮抗剂（MRA）。根据所使用的抗高血压药物类型，幸存者和非幸存者之间无显著差异。二元逻辑回归分析显示，所使用的抗高血压药物类型对死亡率无影响[ACEI/ARB的比值比（OR）=0.527（0.130 - 2.138），p = 0.370；CCB的OR = 0.731（0.296 - 1.808），p = 0.498；利尿剂的OR = 0.673（0.254 - 1.782），p = 0.425；β受体阻滞剂的OR = 1.846（0.688 - 4.950），p = 0.223；α受体阻滞剂的OR = 0.389（0.089 - 1.695），p = 0.208；MRA的OR = 1.372（0.107 - 17.639），p = 0.808]。
所使用的抗高血压药物类型对COVID-19高血压患者的临床病程和死亡率无影响。住院期间应继续使用这些药物治疗高血压。
